Arix Bioscience PLC (LON:ARIX) portfolio company Aura Biosciences has presented updated clinical data from its ongoing Phase 1b/2 clinical trial of its first-line treatment for a rare but potentially fatal form of eye cancer.
The data was presented to the 43rd Annual Macula Society meeting in San Diego and demonstrated multiple administrations of light-activated AU-011 were well-tolerated in patients suffering from primary choroidal melanoma.
Tumour control and vision preservation data continue to be supportive of the planned Phase 3 registration trial in the second half of 2020, the statement added.
Cadmus Rich, Aura’s chief medical officer and head of research and development, said: “The high tumour control rates observed to date, together with the high rate of vision preservation, including in patients at high risk for vision loss with sub-macular and peripapillary tumours continue to support AU-011’s significant potential to change the treatment paradigm for patients battling choroidal melanoma.”
A biotech investment company, Arix has a portfolio of sixteen investee companies that have numerous treatments currently going through clinical trials.